Back to Authors

Kumar, Shaji

https://orcid.org/0000-0001-5392-9284

A5026574827 | I1330342723

Mayo Clinic

Citations 1268

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8092-8093

10.1182/blood-2022-164617

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10033-10035

10.1182/blood-2022-169589

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10068-10070

10.1182/blood-2022-162754

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10942-10944

10.1182/blood-2022-164785

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4360-4361

10.1182/blood-2022-168602

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal A

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7292-7293

10.1182/blood-2022-163260

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10150-10153

10.1182/blood-2022-163335

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10017-10019

10.1182/blood-2022-167181

Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7182-7184

10.1182/blood-2022-156078

A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7180-7181

10.1182/blood-2022-170749